Medtronic Looks At Implantable Pancreas In Europe, Mulls U.S. Plans
This article was originally published in The Gray Sheet
Executive Summary
Despite small glimpses of success with a fully implantable system to monitor glucose in a diabetic's bloodstream and automatically regulate insulin therapy, Medtronic is still mulling whether this approach will ultimately be the focus of its diabetes management program
You may also be interested in...
Overnight Blood Sugar Control Is Within Reach, Study Indicates
Results from an ongoing study using Medtronic's Paradigm real-time insulin pump and continuous glucose monitoring system show early promise for overnight glucose control in diabetics
Medtronic Moves Closer To Closed-Loop Diabetes Care With Paradigm
Earlier-than-anticipated approval of its Paradigm real-time insulin pump and continuous glucose monitoring system again puts Medtronic one step ahead of the competition in moving toward "closed-loop" diabetes management, the company suggests
Dexcom Moves Quickly To Tango With Medtronic In Next-Gen Glucose Testing
Eager to hasten adoption of its second-to-market STS continuous glucose monitoring system, DexCom plans to embark any day on a nationwide launch of the just-approved device